Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast and Market AnalysisDocument Transcript
Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast and MarketAnalysisReport Details:Published:November 2012No. of Pages: 51Price: Single User License – US$6995Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast and Market AnalysisSummaryGlobalData has released its new PharmaPoint Drug Evaluation report, Xeljanz (tofacitinib)(Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic,with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapiesawaiting approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, andRigel/AZ’s SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in theattempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles areproven once they enter the market.Pfizer has developed Xeljanz (tofacitinib;formerly known as tasocitinib), an oral, small-moleculeinhibitor of JAK3 kinase for the treatment of RA, psoriasis, psoriatic arthritis, ankylosingspondylitis, Crohn’s disease, ulcerative colitis, transplant rejection, and dry eye syndrome. Xeljanz(tofacitinib) is the most advanced kinase inhibitor in development for RA and is a first-in-classproduct. Xeljanz (tofacitinib) targets the JAK pathway, thus disrupting the intracellular signalpathway through which cytokines regulate immune responses.Scope- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatmentguidelines as well as an overview on the competitive landscape.- Detailed information on Xeljanz (tofacitinib) including product description, safety and efficacyprofiles as well as a SWOT analysis.- Sales forecast for Xeljanz (tofacitinib) for the top eight countries from 2011 to 2022.- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan andAustralia.
Reasons to buy- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape forrheumatoid arthritis.- Effectively plan your M&A and partnership strategies by identifying drugs with the most promisingsales potential- Make more informed business decisions from insightful and in-depth analysis of Xeljanz(tofacitinib) performance- Obtain sales forecast for Xeljanz (tofacitinib) from 2011 to 2022 in (the US, France, Germany, theUK, Italy, Spain, Japan and Australia)Get your copy of this report @http://www.reportsnreports.com/reports/213174-xeljanz-tofacitinib-rheumatoid-arthritis-forecast-and-market-analysis.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 41.1 List of Tables 61.2 List of Figures 62 Introduction 72.1 Catalyst 72.2 Related Reports 83 Disease Overview 103.1 Etiology and Pathophysiology 103.1.1 Etiology 103.1.2 Pathophysiology 103.1.3 Prognosis 133.1.4 Quality of Life 133.2 Symptoms 144 Disease Management 154.1 Overview 154.2 Diagnosis 154.3 Treatment 175 Competitive Assessment 215.1 Overview 215.2 Strategic Competitor Assessment 216 Opportunity and Unmet Need 236.1 Overview 236.2 Unmet Needs 246.2.1 More rheumatologists in the field and physician knowledge of the disease 246.2.2 More cost-effective therapies through oral formulation and biosimilars 24
6.2.3 The development of predictive tests and discovery of biomarkers 256.2.4 The discovery of curative therapies 256.2.5 Improved drug safety and efficacy profiles 256.3 Gap Analysis 266.4 Opportunities 276.4.1 Predictive tools for diagnosis and treatment 276.4.2 Target specificity 277 Pipeline Assessment 287.1 Overview 287.2 Promising Drugs in Clinical Development 298 Xeljanz (tofacitinib) 318.1 Overview 318.2 Efficacy 328.3 Safety 348.4 Dosing and Formulation 368.5 Potential Clinical Positioning 368.6 Potential Commercial Positioning 368.7 Pricing and Reimbursement 368.8 SWOT Analysis 378.9 Forecast 379 Appendix 399.1 Abbreviations 399.2 Bibliography 419.3 Methodology 469.4 Forecasting Methodology 469.4.1 Diagnosed Rheumatoid Arthritis Patients 469.4.2 Percent Drug-treated Patients 469.4.3 General Pricing Assumptions 479.4.4 Pricing of Pipeline agents 489.5 Physicians and Specialists Included in this Study 489.6 Primary Research - Prescriber Survey 499.7 About the Authors 499.7.1 Analysts 499.7.2 Global Head of Healthcare 509.8 About GlobalData 509.9 Contact Us 519.10 Disclaimer 511.1 List of TablesTable 1: Symptoms of Rheumatoid Arthritis 14Table 2: Treatment Guidelines for Rheumatoid Arthritis 18Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market 20
Table 4: Treatment Guidelines for Rheumatoid Arthritis 22Table 5: Overall Unmet Needs - Current Level of Attainment 23Table 6: Clinical Unmet Needs - Gap Analysis, 2012 27Table 7: Rheumatoid Arthritis - Phase Pipeline, 2012 29Table 8: Comparison of Therapeutic Classes in Development for RA, 2012 30Table 9: Product Profile - Xeljanz (tofacitinib) 32Table 10: Clinical Trial Locations by Country for Xeljanz (tofacitinib) 32Table 11: ORAL Standard ACR 20 Responses for Xeljanz (tofacitinib) vs. Placebo vs. Humira atMonth 6 33Table 12: ORAL Step ACR 20, 50, 70 Responses for Xeljanz (tofacitinib) vs. Placebo at Month Six33Table 13: Efficacy Issues Regarding Xeljanz (tofacitinib) Determined by FDA Advisory Panel, May2012 34Table 14: Safety Issues Regarding Xeljanz (tofacitinib) Determined by FDA Advisory Panel, May2012 35Table 15: Xeljanz (tofacitinib) Clinical Trial Mortalities as of September 29, 2011 35Table 16: Xeljanz (tofacitinib) SWOT Analysis, 2012 37Table 17: Global Sales Forecasts ($m) for Xeljanz (tofacitinib) 38Table 18: Physicians Surveyed, By Country 491.2 List of FiguresFigure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis 10Figure 2: Rheumatoid Arthritis Biologic Drug Targets 12Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria PointSystem 16Figure 4: Severity of Rheumatoid Arthritis 17Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations*19Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2012-2022 29Contact: email@example.com for more information.